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INTRODUCTION
Activating mutations in genes encoding components of the Ras-
MAPK pathway have not only been identified in various tumor
types, but also in developmental disorders (Aoki et al., 2008;
Karnoub and Weinberg, 2008; Schubbert et al., 2007). Germline
mutations in genes of the Ras-MAPK pathway have been found
in a group of genetic syndromes that are collectively called
RASopathies, including Noonan syndrome (OMIM 163950),
LEOPARD syndrome (OMIM 151100), Costello syndrome
(OMIM 218040) and cardio-facio-cutaneous (CFC) syndrome
(OMIM 115150) (Denayer et al., 2008; Tidyman and Rauen, 2009).
These syndromes are characterized by partially overlapping
symptoms, including distinctive craniofacial features and
cardiovascular anomalies, and they are genetically heterogeneous,
with mutations in known disease genes accounting for 70-80% of
the cases.
Noonan syndrome is a relatively common dominantly inherited
genetic disorder characterized by congenital heart defects, reduced
growth, facial dysmorphism and variable congenital defects (Gelb
and Tartaglia, 2006). The syndrome is caused by activating
mutations in genes encoding upstream factors of the Ras-MAPK
pathway, including PTPN11 (Shp2) (Tartaglia et al., 2001) and SOS1
(Roberts et al., 2007; Tartaglia et al., 2007), as well as KRAS (Pandit
et al., 2007; Schubbert et al., 2006), SHOC2 (Cordeddu et al., 2009)
and the more downstream signal transducers RAF1 and BRAF
(Pandit et al., 2007; Razzaque et al., 2007; Tartaglia et al., 2007).
The most recent addition to the group of genes that are associated
with Noonan syndrome is NRAS. In a cohort of 917 individuals
with typical features of Noonan syndrome, who were negative for
mutations in previously known Noonan-syndrome-associated
genes, two distinct mutations, T50I and G60E, were identified in
NRAS in four individuals. Mutant N-Ras-G60E and, to a lesser
extent, N-Ras-T50I activated MAPK signaling in cells (Cirstea
et  al.,  2010). Activation of N-Ras was previously found to be
associated with acute myeloid leukemia (AML) (Bos et al., 1985;
Bos et al., 1987) and melanoma (van ’t Veer et al., 1989), and a
germline activating mutation in NRAS causes autoimmune
lymphoproliferative syndrome (Oliveira et al., 2007).
Here, we report the identification of a new mutation in N-Ras
in an individual with Noonan syndrome that results in an amino
acid substitution, I24N. Mutant N-Ras-I24N activates downstream
MAPK signaling. We used zebrafish embryos to assess the in vivo
effects of dominant mutations in genes that are associated with
Noonan syndrome, as we and others have done previously
(Anastasaki et al., 2009; Jopling et al., 2007; Razzaque et al., 2007;
Stewart et al., 2010). Expression of N-Ras-I24N or two other
Noonan-syndrome-associated N-Ras mutants, T50I or G60E, in
zebrafish embryos resulted in severe developmental defects during
epiboly and gastrulation that resemble the defects observed in
Disease Models & Mechanisms 393
Disease Models & Mechanisms 4, 393-399 (2011) doi:10.1242/dmm.007112
1Hubrecht Institute–KNAW and University Medical Center Utrecht, Uppsalalaan 8,
3584 CT Utrecht, The Netherlands
2University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The
Netherlands
3Radboud University Nijmegen Medical Centre, Geert Grooteplein-Zuid 26 28,
6525 GA Nijmegen, The Netherlands
4Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The
Netherlands
5Institute of Biology Leiden, Leiden University, Einsteinweg 55, 2333 CC Leiden,
The Netherlands
*These authors contributed equally to this work
‡Author for correspondence (j.denhertog@hubrecht.eu)
Received 19 October 2010; Accepted 26 November 2010
© 2011. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution
Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which
permits unrestricted non-commercial use, distribution and reproduction in any medium provided
that the original work is properly cited and all further distributions of the work or adaptation are
subject to the same Creative Commons License terms.
SUMMARY
Noonan syndrome is a relatively common developmental disorder that is characterized by reduced growth, wide-set eyes and congenital heart
defects. Noonan syndrome is associated with dysregulation of the Ras–mitogen-activated-protein-kinase (MAPK) signaling pathway. Recently, two
mutations in NRAS were reported to be associated with Noonan syndrome, T50I and G60E. Here, we report a mutation in NRAS, resulting in an I24N
amino acid substitution, that we identified in an individual bearing typical Noonan syndrome features. The I24N mutation activates N-Ras, resulting
in enhanced downstream signaling. Expression of N-Ras-I24N, N-Ras-G60E or the strongly activating mutant N-Ras-G12V, which we included as a
positive control, results in developmental defects in zebrafish embryos, demonstrating that these activating N-Ras mutants are sufficient to induce
developmental disorders. The defects in zebrafish embryos are reminiscent of symptoms in individuals with Noonan syndrome and phenocopy the
defects that other Noonan-syndrome-associated genes induce in zebrafish embryos. MEK inhibition completely rescued the activated N-Ras-induced
phenotypes, demonstrating that these defects are mediated exclusively by Ras-MAPK signaling. In conclusion, mutations in NRAS from individuals
with Noonan syndrome activated N-Ras signaling and induced developmental defects in zebrafish embryos, indicating that activating mutations
in NRAS cause Noonan syndrome.
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response to a known Noonan-associated gene. Interestingly,
pharmacological inhibition of MEK rescued these activated N-Ras-
induced developmental defects, demonstrating that the activated
N-Ras-induced defects are caused by activation of MAPK signaling.
RESULTS AND DISCUSSION
In search of the genetic cause of Noonan syndrome, we resequenced
all exons of NRAS in a Dutch cohort of 56 Noonan syndrome
patients lacking mutations in known Noonan-syndrome-associated
genes. We found a single individual heterozygous for a nucleotide
mutation in exon 2, c.71T>A, resulting in the amino acid
substitution p.I24N (Fig. 1A). The 30-year-old patient had been
diagnosed with Noonan syndrome and demonstrated the facial
features, low posterior hairline, webbing of the neck, pectus
excavatum, cryptorchism, mild learning difficulties and mild short
stature characteristic of the syndrome. Assessment at birth and at
age 15 revealed no heart abnormalities. His parents did not exhibit
classical Noonan features and did not harbor the mutation in NRAS
(Fig. 1Ab,c), demonstrating the de novo origin of the mutation. To
exclude the possibility of somatic mosaicism, NRAS was
resequenced in skin fibroblasts and buccal epithelial cells from
sputum from the patient, both of which showed the c.71T>A
mutation heterozygously (Fig. 1Ad,e), which supports the
conclusion that the patient has a germline NRAS mutation. The
c.71T>A mutation was not found in 100 controls without Noonan
syndrome.
The surrounding sequence of I24 is identical in N-Ras, K-Ras
and H-Ras, and is localized between the P-loop, involved in
nucleotide binding, and Switch I, involved in effector binding (Fig.
1B). Mutations in I24 have not previously been identified in any
Ras isoform. Whereas efficient GTP hydrolysis is blocked in
oncogenic Ras with G12V or Q61K mutations, resulting in activated
Ras, such an effect of I24N is unlikely, given the location of I24 in
N-Ras (Fig. 1B,C). Recently, H-Ras mutations in Gln22 (Q22) were
described in three patients diagnosed with RASopathies,
specifically Noonan syndrome (Q22R), CFC syndrome (Q22E) and
Costello syndrome (Q22K) (van der Burgt et al., 2007; Zenker et
al., 2007). Although biochemical data that the Q22 mutations
activate H-Ras was not provided, other patients with similar
symptoms contained well-known activating mutations in H-Ras,
including G12V, G12S, G60R or E63K. Hence, it is likely that the
Q22 mutations activate H-Ras, suggesting an important regulatory
role for the region between the P-loop and Switch I, which includes
N-Ras I24 (Fig. 1B).
Two mutations in NRAS were previously identified in Noonan
syndrome patients, one of which (G60E) is characterized as highly
GTP bound, whereas the other (T50I) showed normal GTP loading
(Cirstea et al., 2010). To assess the activation state of N-Ras-I24N,
GTP-bound Ras was selectively precipitated from cells stimulated
with serum. We found that a higher proportion of N-Ras-I24N was
precipitated relative to wild-type N-Ras (Fig. 2A). A similar effect
was observed for N-Ras-G12V and N-Ras-G60E, but not for N-
Ras-T50I. In the absence of serum, out of these mutants only
oncogenic N-Ras-G12V was highly GTP bound. These results
group N-Ras-I24N in the class of ‘mild activating’ mutations, the
activation of which is dependent on upstream signaling. Mild
activating mutations are commonly associated with Noonan and
Noonan-related syndromes (Tidyman and Rauen, 2009). The side
chain of Ile24 (I24) in the 1-helix points towards the 2-strand
(Fig. 1C) and mutation to Asn (N) would probably result in
repulsing forces between the 1-helix and the 2-strand, thereby
destabilizing the fold of the G protein. Hence, the nucleotide affinity
might be weakened, resulting in an increased exchange rate and
therefore higher GTP loading under physiological conditions,
because the GTP:GDP ratio is ~9:1 in cells. This would be in
agreement with the ‘mild activation’ character of the I24N mutant.
We next investigated MAPK activation, a downstream
consequence of N-Ras activation, in 293T cells expressing N-Ras-
I24N and found robust MAPK phosphorylation in the presence of
serum in comparison with wild-type N-Ras (Fig. 2B). N-Ras-G60E
and the positive control, N-Ras-G12V, also enhanced MAPK
activation, but N-Ras-T50I did not, which is in agreement with a
weak or no increase in Ras-binding domain (RBD) binding (Fig.
2A). Together, these results demonstrate that the I24N amino acid
substitution increases the fraction of active N-Ras and enhances
MAPK activation, which might be due to enhanced GTP loading
from subtle changes in the conformation of the GTP-binding
pocket.
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Fig. 1. Identification and localization of an I24N amino acid substitution in N-Ras in an individual with typical features of Noonan syndrome. (A)The
heterozygous c.71T>A nucleotide substitution in exon 2 that was first identified in the patient (a) was not detected in the father (b) or the mother (c) and was
detected in DNA isolated from fibroblasts (d) and sputum (e) of the patient. (B)Genomic organization (top), protein structure (middle) and sequence of N-Ras
around Ile24 (bottom), which is encoded by exon 2, which is located on helix 1, between the P-loop (P) and switch I (I). Switch II (II) and the hypervariable region
(HVR) are also indicated in the protein structure. (C)Ribbon representation of N-Ras•GDP (Protein Data Bank code: 3con), with GDP (blue) and residues Ile24,
Thr50 and Gly60 highlighted as ball and stick representation. Missing connectivity for residues 61 to 71 is indicated by a dotted line.
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To evaluate the functional consequences of activating mutations
in Noonan-syndrome-associated genes at the organismal level, we
and others have used zebrafish as a model system (Anastasaki et
al., 2009; Jopling et al., 2007; Razzaque et al., 2007; Stewart et al.,
2010). Mutant N-Ras was expressed in zebrafish embryos at the
one-cell stage by injection of synthetic RNA encoding wild-type
or mutant N-Ras. We first established that MAPK phosphorylation
is enhanced in response to N-Ras-I24N, N-Ras-G60E and N-Ras-
G12V, relative to wild-type N-Ras in zebrafish embryos (Fig. 2C),
which is consistent with our results in 293T cells (Fig. 2B). N-Ras-
T50I only weakly activated MAPK phosphorylation in zebrafish
embryos.
Morphological defects in embryos expressing mutant forms of
N-Ras were apparent at 11 hours post-fertilization (hpf). The
morphology of the nras-injected embryos was monitored by time-
lapse imaging. Notably, N-Ras-I24N seemed to induce epiboly and
gastrulation defects, as reflected in the reduced body axis extension
at 14 hpf (supplementary material Fig. S1) and the oval shape of
the embryos at epiboly (Fig. 3A). Severe morphological defects were
not observed at 11 hpf or 24 hpf in embryos injected with RNA
encoding wild-type N-Ras. The morphological phenotypes induced
by N-Ras-I24N at 24 hpf ranged in severity from completely
disorganized embryos to mildly affected shorter embryos (Fig. 3A).
The epiboly defects were quantified by analysis of the ratio of
the major and minor embryonic axes (Fig. 3B). Non-injected
control embryos were almost perfect spheres and the ratio of the
major and minor embryonic axes was approximately 1. Injection
of RNA encoding N-Ras-I24N resulted in a significant increase in
the major:minor axis ratio, whereas the ratio with wild-type N-Ras
was similar to non-injected controls. N-Ras-G12V from tumors and
N-Ras-G60E from Noonan patients both strongly affected the
major:minor axis ratio, whereas N-Ras-T50I only had mild effects
(Fig. 3C). Activating mutants in B-Raf were recently reported to
induce defects in epiboly (Anastasaki et al., 2009); thus, we included
the robustly active B-Raf-V600E mutant as a positive control in
our assay. As expected, this mutant exerted a strong effect on the
major:minor axis ratio, whereas wild-type B-Raf had no effect (Fig.
3C).
The effects of the N-Ras mutants on early zebrafish development
were probably due to activation of the MAPK pathway. Using the
MEK inhibitor CI-1040 to suppress downstream MAPK activation,
we found that the deleterious effects of N-Ras-I24N on epiboly and
later development were completely rescued by inhibition of MEK
(Fig. 3A). Quantification of the epiboly defects confirmed the
complete rescue of the N-Ras-I24N, N-Ras-G12V, N-Ras-G60E and
N-Ras-T50I mutants, as well as B-Raf-V600E (Fig. 3C). Taken
together, our data demonstrate that N-Ras-I24N is a functionally
activated mutant of N-Ras that induces developmental defects,
similar to those induced by N-Ras-G12V and N-Ras-G60E in a
pathway requiring N-Ras-mediated activation of MAPK. It should
be noted that the rescues were mediated by a pulse of MEK inhibitor
between 4.5 and 5.5 hpf, whereas a more prolonged exposure to
the inhibitor induced developmental defects on its own, consistent
with a previous report (Anastasaki et al., 2009).
N-Ras-I24N is a mildly activating mutant of N-Ras, which
requires serum to be present for activation of the Ras-MAPK
pathway in 293T cells (Fig. 2B). Fibroblast growth factor receptor
(FGFR) signaling is an upstream factor in convergence and
extension cell movements during gastrulation. We assessed the
effect of the FGFR inhibitor SU5402 on N-Ras-I24N-induced
developmental defects. Interestingly, we observed that SU5402
partially rescued the gastrulation defects that were induced by N-
Ras-I24N, whereas SU5402 at these concentrations had no effect
on non-injected control embryos (Fig. 3D). We conclude that
upstream FGFR signaling is required for the developmental defects
that are induced by N-Ras-I24N.
To further characterize the activated N-Ras-induced epiboly and
gastrulation cell-movement defects, we used classical molecular
markers for in situ hybridization. Convergence and extension cell
movements during gastrulation shape the embryos, making the
embryo narrower (convergence) and longer (extension) (Solnica-
Krezel, 2006). A well-known marker for convergence and extension
cell movements during gastrulation is the ratio between the width
of the krox20-positive rhombomeres 3 and 5 and the distance
between somites 1 and 8, visualized by myoD staining at the eight-
somite stage (12 hpf) (Li et al., 2008). Injection of N-Ras-I24N led
to widening of the embryos at 12 hpf (Fig. 4A). N-Ras-G12V and
N-Ras-G60E had extreme effects, whereas N-Ras-T50I resembled
wild-type N-Ras (Fig. 4A). Quantification of the ratio of the width
to the length revealed significant increases in this ratio in embryos
injected with RNA encoding mutant N-Ras-G12V, N-Ras-I24N and
N-Ras-G60E, compared with wild-type nras-injected and non-
injected controls (Fig. 4B). N-Ras-T50I also induced a significant
albeit small increase in the ratio, relative to wild-type N-Ras.
Another marker for convergence and extension cell movements is
dlx3 and hgg1 staining at the one-somite stage (10 hpf) (Jopling
and den Hertog, 2005; van Eekelen et al., 2010). These markers
indicate that N-Ras-G12V, N-Ras-I24N and N-Ras-G60E induced
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Fig. 2. I24N mutation activates N-Ras and downstream signaling.
(A)Active, GTP-bound Ras was selectively precipitated from lysates of growing
293T cells transfected with RNA encoding N-Ras (wild type or mutants) with
the Ras-binding domain (RBD) of Raf-1. Precipitated Ras was detected by
immunoblotting using a Ras-specific antibody. The amount of Ras in the
lysates was monitored by immunoblotting. (B)Transfected, growing 293T cells
expressing N-Ras (mutants) were lysed and equal amounts of these lysates
were loaded onto SDS-PAGE gels, blotted and probed with antibody against
phospho-MAPK, or against Tubulin as a loading control. (C)Synthetic RNA
(5 pg) encoding wild-type or mutant N-Ras was injected into zebrafish
embryos at the one-cell stage. Embryos were lysed at 24 hpf and loaded onto
SDS-PAGE gels, blotted and probed with antibodies against phospho-MAPK,
MAPK and, as a loading control, against actin.
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significant defects in convergence and extension cell movements
as well (supplementary material Fig. S2). Taken together, these
results demonstrate that activating N-Ras mutants induce
gastrulation cell-movement defects at severities that parallel the
capacity to activate MAPK.
To monitor gastrulation cell movements directly, we have
developed time-lapse fluorescent microscopy of zebrafish embryos
injected with fluorescent Histone H1 protein, which labels all nuclei
(van Eekelen et al., 2010). Using this cell tracking technology, we
found that expression of N-Ras-I24N resulted in a 10% reduction
in convergence and 6% reduction in extension of paraxial
mesendodermal cells, compared with embryos injected with RNA
encoding wild-type N-Ras. These results are statistically significant
(P0.001) because they are based on more than 1000 cell tracks
each. One of the underlying mechanisms of convergence and
extension is cell intercalation and mediolateral elongation (Concha
and Adams, 1998; Myers et al., 2002). By cell membrane labeling
and ratiometric analysis of cell shape and orientation, we found
that cell polarization is reduced upon N-Ras-I24N expression
(supplementary material Fig. S3), which is consistent with the
observed convergence and extension cell-movement defects.
One of the hallmarks of Noonan syndrome is hypertelorism and
we have demonstrated before that expression of mutant Shp2 leads
to craniofacial defects, including wide-set eyes, in zebrafish
embryos (Jopling et al., 2007). We assessed defects in craniofacial
cartilage structures using the transgenic Tg(–4.9sox10:EGFP)ba2
zebrafish line, which expresses GFP in all neural crest cells (Carney
et al., 2006). The angle of the ceratohyal is a direct measure for the
width and the bluntness of the head (Fig. 4C), and is an excellent
marker for hypertelorism. Expression of N-Ras-I24N led to a
significant increase in the angle of the ceratohyal (P<0.05; Student’s
t-test) (Fig. 4C,D) and hence we conclude that N-Ras-I24N
expression induced craniofacial defects in zebrafish embryos that
are reminiscent of the symptoms in individuals with Noonan
syndrome.
In conclusion, we report an activating mutation in N-Ras, I24N,
that is associated with Noonan syndrome. Interestingly, our in vivo
data in zebrafish embryos (Figs 3, 4) demonstrate for the first time
that the activating N-Ras mutants, I24N and G60E, are sufficient
for inducing developmental defects that resemble the defects
induced by active mutants of downstream factors, B-Raf, Raf-1 and
MEK, from Noonan and related syndromes (Anastasaki et al., 2009),
dmm.biologists.org396
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Fig. 3. Active N-Ras-induced early
developmental defects in zebrafish embryos.
(A)Embryos were injected at the one-cell stage
with synthetic RNA (5 pg) encoding N-Ras (wild
type or mutant), and morphology was assessed
at 11 hpf and 24 hpf. Injected embryos were
incubated with MEK inhibitor CI-1040 (1M)
from 4.5 hpf until 5.5 hpf. Representative
batches of embryos are depicted here. Scale
bars: 1 mm. (B)The severity of the phenotype
was determined by assessment of the shape of
the embryos at 11 hpf. The ratio of the length of
the major and minor axes was determined, as
indicated in examples of severely affected (top),
mildly affected (middle) and a control (bottom)
embryos. Scale bar: 500m. (C)Quantification
of the ratio of the major and minor axes upon
injection of synthetic RNAs encoding wild-type
(WT) or mutant N-Ras as indicated. As a
negative control, the major:minor axis ratio was
determined in non-injected control embryos
(NIC). In addition, RNA encoding wild-type B-Raf
or activated mutant B-Raf-V600E was injected.
Blue bars: embryos were mock treated (0.1%
DMSO); red bars: embryos were treated with
MEK inhibitor CI-1040 (1M). (D)Embryos were
treated with the FGFR inhibitor SU5402 (5M)
from 4.5 hpf onwards and the phenotype was
quantified as in C. Blue bars: mock-treated (0.1%
DMSO); red bars: FGFR-inhibitor-treated.
Averages of the major:minor axis ratio are
depicted in panels C and D and the s.e.m. is
indicated; Student’s t-tests (two-tailed,
assuming unequal variance) were performed
between mutant and wild-type N-Ras-injected
groups; *P<0.001. The total number of embryos
from two to six independent experiments that
were used per condition are indicated (n).
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and hence firmly establish NRAS as a gene that causes Noonan
syndrome upon activation. The observed craniofacial defects in
zebrafish embryos (Fig. 4C,D) actually resemble symptoms in
individuals with Noonan syndrome. Taken together, our in vivo
data demonstrate that NRAS is a bona fide Noonan-associated gene
that has a causal role in the syndrome.
Ras mutations found in human cancer are thought to contribute
to disease by activating at least three major downstream signaling
pathways, i.e. the Raf-MAPK pathway, the PI3K-PKB/AKT pathway
and the RalGDS-Ral pathway. In the case of Noonan N-Ras
mutants, it becomes apparent that Raf-MAPK activation is
sufficient. Mutational activation of B-Raf causes developmental
defects in zebrafish that are identical to those in the activating N-
Ras mutants, and pharmacological inhibition of MEK using CI-
1040 completely rescues these developmental defects. MEK and/or
MAPK inhibitors are currently in clinical trials for the treatment
of cancers harboring active RAS mutations. This raises the
interesting possibility that these inhibitors might also be appropriate
for the treatment of developmental disorders that are caused by
RAS mutations that depend exclusively on Raf-MAPK activation
to convey their pathology.
METHODS
Experimental subjects
Written informed consent was obtained from all subjects and/or
their legal representatives, and the work was done according to the
guidelines of the medical ethical committee of Radboud University,
Nijmegen, The Netherlands.
All procedures involving experimental animals were performed
in compliance with local animal welfare laws, guidelines and
policies. 
DNA isolation and sequencing
DNA was isolated from blood, fibroblasts or sputum. Mutational
screening of NRAS (ENSG00000213281) was performed by PCR
of all four exons, using the following primers: NRAS-1-F 5-
CGCCAATTAACCCTGATTAC-3; NRAS-1-R 5-AGAGAC -
AGGATCAGGTCAGC-3; NRAS-2-F 5-ATAGCATTGCA -
TTCCCTGTG-3; NRAS-2-R 5-CACAAAGATCATCC TT -
TCAGAG-3; NRAS-3-F 5-CCACTGTACCCAGCCTAATC-3;
NRAS-3-R 5-AAACTCTTGCACAAATGCTG-3; NRAS-4-R
5-CCTCCAAATTGCCCAATAC-3; NRAS-4-F 5-ATTTG -
GATTGTGTCCGTTG-3.
Bidirectional resequencing was performed using a commercial
sequencing kit (ABI BigDye Terminator Sequencing kit V2.1;
Applied Biosystems) and an automated capillary sequencer (ABI
3730; Applied Biosystems).
RBD assays and MAPK phosphorylation
Ras activation was determined with the minimal RBD of Raf-1
as an activation-specific probe, as described previously (de Rooij
and Bos, 1997). Briefly, 293T cells [American Type Culture
Collection (ATCC)] were transfected with CMV-promoter-driven
expression vectors for N-Ras and mutants. The cells were lysed
and active Ras was precipitated with glutathione-agarose beads
coupled to GST-RBD. Precipitated N-Ras was detected by western
blotting using an N-Ras-specific antibody (Santa Cruz). Zebrafish
embryos (24 hpf ) were lysed in boiling sample buffer and equal
amounts of lysate were loaded onto SDS-PAGE gels. MAPK
phosphorylation was established by western blotting using
phospho-MAPK-specific mouse monoclonal antibody (mAb; Cell
Disease Models & Mechanisms 397
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Fig. 4. Active N-Ras induced convergence and extension cell-movement
defects and craniofacial defects. (A)In situ hybridization was performed
using embryos at the eight-somite stage (~12 hpf) using krox20 and myod-
specific probes: non-injected control (NIC) embryos or embryos injected with
synthetic RNA encoding wild-type (WT) N-Ras or mutants, as indicated, were
used. Dorsal views of flat-mounted embryos are depicted, anterior to the top.
Scale bar: 250m. (B)The ratio of the width of the krox20 staining and the
length from the first to the eighth somite was determined using ImageJ
software and is depicted here. Error bars indicate s.e.m.; Student’s t-tests (two-
tailed, assuming unequal variance) were performed between mutant and
wild-type N-Ras-injected groups; *P<0.005. Total numbers of embryos that
were used for the analyses are indicated (n). (C)Embryos from the
Tg(–4.9sox10:EGFP)ba2 transgenic line, in which neural crest cells are marked,
were injected at the one-cell stage with RNA encoding N-RAS-I24N. The
ceratohyal is marked by GFP in the transgenic embryos at 4 dpf and lines (red)
were drawn demarcating the ceratohyal, facilitating analysis of the angle in
the ceratohyal, which is a direct marker for the width and bluntness of the
heads of these embryos. Representative images of a non-injected control (NIC)
and a N-RAS-I24N-injected embryo are depicted. Scale bar: 100m.
(D)Quantification of the angle of the ceratohyal. The number of individuals
used (n) is indicated. A Student’s t-test was performed; asterisk indicates
significant difference, P<0.005.
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Signaling), and equal loading was monitored using tubulin-
specific mouse mAb (Calbiochem), MAPK-specific rabbit mAb
(Cell Signaling) and actin-specific rabbit polyclonal antibody
(Sigma).
Zebrafish, injections and in situ hybridization
Zebrafish were kept and embryos were raised under standard
conditions. Zebrafish were staged as described before (Westerfield,
1995). Constructs encoding human N-Ras and mutants were
derived by PCR and verified by sequencing. The wild-type and
mutant B-Raf-encoding constructs (Anastasaki et al., 2009) were
a gift from Liz Patton. 5-capped sense RNAs were synthesized
using mMessage mMachine kit (Ambion). Synthetic RNA was
injected at the one-cell stage. The amount of RNA encoding wild-
type N-Ras was titrated down to an amount that did not induce
morphological defects by itself (5 pg). Subsequently, 5 pg of all
mutants was injected at the one-cell stage. 30 pg RNA encoding
wild-type or mutant B-Raf was injected at the one-cell stage
(Anastasaki et al., 2009). Phenotypes were assessed at the indicated
stages. At 11 hpf, batches of embryos were photographed and the
ratio of major:minor axis of each embryo was determined
individually using ImageJ software. Pharmacological inhibitors
were added directly to the embryo medium at 4.5 hpf. CI-1040
(Selleck Chemicals) was removed at 5.5 hpf to avoid inadvertent
side effects of prolonged treatment, whereas SU5402 (Merck) was
left on the embryos for the duration of the experiment. In situ
hybridizations were performed essentially as described (Thisse et
al., 1993) using probes specific for myod and krox20 at the eight-
somite stage (~12 hpf ) (Li et al., 2008). Quantification of
convergence and extension cell-movement defects by analysis of
the ratio of the width of krox20 staining and the length from somite-
1 to somite-8 was done using ImageJ software as described before
(van Eekelen et al., 2010).
Analysis of cell movement and polarization
Mesendodermal cell tracking was performed exactly as described
before (van Eekelen et al., 2010). Briefly, embryos were injected at
the one-cell stage with Histone-H1 tagged with Alexa Fluor 488
from Molecular Probes (H1). The embryos were dechorionated and
mounted at shield stage in 1% low-melting-point agarose. A Leica
SP2 confocal microscope with a 40 objective was used for live
imaging and time points were recorded every 2 minutes from shield
stage until the one-somite stage. Time-lapse images were analyzed
using ImageJ (http://rsbweb.nih.gov/ij/). Following image
processing, uniform objects were readily traced, and convergence
and extension cell movements quantified. Statistical analysis was
performed by the Microsoft Excel Student t-test assuming unequal
variances with alpha0.05.
Craniofacial defects
Craniofacial defects were determined by measurement of the
ceratohyal angle at 5 dpf. The Tg(–4.9sox10:EGFP)ba2 transgenic
line, in which neural crest cells are marked(Carney et al., 2006),
was used, facilitating detection of the ceratohyal. The angle was
defined by two lines, one parallel to the left part of the ceratohyal
and the other parallel to the right part (cf. Fig. 4C).
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TRANSLATIONAL IMPACT
Clinical issue
Noonan syndrome is a relatively common, dominantly inherited genetic
disorder characterized by congenital heart defects, reduced growth, facial
dysmorphism and other variable congenital defects. The syndrome is caused
by activating mutations in genes encoding factors of the RAS-MAPK signaling
pathway and hence belongs to a group of genetic syndromes that are
collectively called RASopathies. Mutations in known disease-associated genes
are found in 70-80% of patients with Noonan syndrome, and ~50% of patients
have activating mutations in a gene encoding an upstream factor in the RAS-
MAPK pathway [protein-tyrosine phosphatase, non-receptor type 11 (SHP2),
encoded by PTPN11]. The most recent addition to the group of genes that are
associated with Noonan syndrome is NRAS, which encodes a member of the
Ras protein family. 
Results
In this study, the authors report on a mutation in NRAS resulting in an I24N
amino acid substitution that they identified in an individual bearing typical
Noonan syndrome features. The I24N mutation mildly activates N-Ras,
resulting in enhanced downstream signaling, similar to other activating N-Ras
mutations that are associated with Noonan syndrome. By using zebrafish
embryos as a model, they go on to show that expression of I24N or other
disease-associated activating N-Ras mutants causes developmental defects,
including cell migration defects during gastrulation. The craniofacial defects
observed in the zebrafish embryos carrying disease-associated mutations in N-
Ras resemble the defects observed in individuals with Noonan syndrome.
Furthermore, developmental defects induced by activated N-Ras phenocopy
the developmental defects that are induced by the expression of other genes
known to be associated with Noonan syndrome, including PTPN11, in zebrafish
embryos. Finally, they show that pharmacological inhibition of MEK, a
downstream factor in the RAS-MAPK pathway, rescues the phenotype induced
by activating N-Ras mutations, demonstrating that the observed defects are
mediated exclusively by enhanced activation of the RAS-MAPK signaling
pathway. 
Implications and future directions
This study provides new evidence that NRAS is a bona fide Noonan-syndrome-
associated gene and, moreover, that activation of N-Ras can cause the clinical
phenotype. Hence, NRAS should be included in diagnostic screening for
mutations in individuals with symptoms of Noonan syndrome. Notably,
pharmacological inhibition of MEK rescues the developmental defects that are
induced by activated N-Ras. Given that the RAS-MAPK pathway is also
implicated in cancer, developing inhibitors of this pathway has been a major
focus of many pharmaceutical companies, and clinical trials to test them in a
subset of cancer patients are currently underway. Such inhibitors might also
be effective for treating some RASophathies, including Noonan syndrome, that
are caused by hyperactivation of the RAS-MAPK pathway. 
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